Though this could be the result of a mutation at a single locus, we think it is much more likely to be the result of a cross-over within a supergene.
A supergene is a collection of closely linked genes acting as one functional unit and a priori it seems likely that genes which improve the mimetic pattern will tend to become aggregated close together on the same chromosome and they will then be inherited together. In such circumstances crossing-over might occasionally occur and this would produce new forms, and support for the view that this actually happens comes from a consideration of the three rare insects shown in Plate 3. The points to note here (and in the other forms) are the colour of the epaulettes (E), the size of the white patch on the hindwing (W), the colour of the body (B), the presence or absence of tails (T) and the forewing pattern (F). These three rare forms, as well as f. titania and others not shown, can all be accounted for by crossing-over within the supergene, if the order of the loci on the chromosome is TWFEB (see Clarke, Sheppard & Thornton, 1968; Clarke & Sheppard, 1971) .
It was this type of finding [originally in PapiZio dardanus Brown (Clarke & Sheppard, 1956 )] together with many examples of genic interactions in the Papilios, e.g. the situation in the male of P. memnon, which led us to think of similar situations in man, and the blood-group polymorphisms were an obvious parallel. In particular the arguments put forward for the order of the loci on the chromosome in P. memnon are exactly the same as those which Fisher employed to account for the rarer Rh genotypes.
Rhesus and ABO incompatibility between mother and foetus
Plate 4 shows a blood film of a recently delivered woman in whom there has been a considerable transplacental haemorrhage (TPH). If incompatible on the ABO system most of the foetal cells would be rapidly removed by the naturally occurring anti-A or anti-B antibody, and Table 1 shows the extent to which foetal cells are decreased when the baby is ABO incompatible compared with when it is compatible. Levine (1943) first pointed out that ABO incompatibility between mother and baby was protective against Rhesus immunization, but such incompatibility is only present in 20% of cases, and it occurred to us that it might be possible to protect the other 80% by giving anti-Rh antibody after delivery (Finn, 1960) . Such prophylaxis has turned out to be very successful, the failure rate in most centres being about 0.5% at 6 months and another 0.5% by the end of the next Rh-positive pregnancy, making about 1 % in all. This has to be compared with an immuni- zation rate of 8.5% at 6 months and a further 8.5% by the end of the second Rh-positive pregnancy (making 17% in all) if nothing is done. Though these values represent a considerable number of affected babies in a population the size of the United Kingdom, it must be emphasized that the majority of Rh-negative women having Rh-positive ABO compatible babies escape being immunized and some of the reasons for this are known. Most important is that probably about one-third of Rh-negative individuals are incapable of being immunized, no matter how big the stimulus (see later), while in the remaining two-thirds many have no TPH though when they do its size is very relevant to the risk of immunization (Table 2) . Additional but minor factors influencing this are the Rh genotype of the father; cDE/cde is more immunogenic than CDe/cde (Murray, 1957) , and the sex of the baby, boys being more likely to cause antibody formation than girls (Renkonen & Timonen, 1967) . In ABO haemolytic disease protective mechanisms must also be operative, for one in five babies are incompatible with their mothers on this system and yet the disease is comparatively rare. The most important factor is that naturally occurring anti-A and antiB antibodies are mostly 19s and this type of immunoglobulin will not cross the placenta. (In group 0 mothers, however, the plasma contains some 7s antibodies and it is women of this blood type who are most at risk.) Also protective are the blood-group substances, present to a greater or lesser extent in the plasma of the baby, since these will 'mop up' any maternal 7s anti-A or anti-B antibody, the erythrocytes thus being spared. Another factor may be that the A and B antigens on the baby's erythrocytes are immature at birth (see Race & Sanger, 1968) , but an argument against this is that there is rarely any difficulty in the routine grouping of a baby. Further, if lack of development of the antigens were really important it would raise a considerable problem as to how the protective effect of ABO incompatibility against Rh immunization is brought about. Moulinier, Mesnier & Merle (1971) have evidence to suggest that where a woman immunized to Rh also has lymphocytotoxic antibodies against the white cells of her Rh-positive baby, the infant is more likely to be hydropic than if the mother has Rh antibodies alone. However, neither Tovey, Darke & Fraser (1970) nor Imre & Keseru (1970) found this to be the case in their patients, and in a Liverpool series (P. Ewing, personal communication) there was also no evidence of a combined effect. Of eighty-two Rh-negative immunized women, eleven out of the fifty-nine without leucocyte antibodies had hydropic stillbirths, as against four out of the twentythree who had leucocyte antibodies. In Ewing's cases the white-cell typing (performed either against the father's cells or against those of twenty random donors) was done in ignorance of the woman's obstetric history. We feel, therefore, that there is much evidence to suggest that white-cell antibodies are usually harmless as far as haemolytic disease of the newborn (HDN) is concerned, being absorbed by the foetal tissues.
Rhesus and leucocyte incompatibility between mother and foetus

Some details of the prophylaxis of Rh haemolytic disease of the newborn by the giving of anti-D antibody
Data on this are now available from most parts of the world where Rh HDN is a problem, and mention will now be made of centres where there are points of particular interest. Liverpool. Here, with the cooperation of the Department of Obstetrics and Gynaecology, anti-D antibody has been in use since 1966 and Mr Bryan M. Hibbard, Senior Lecturer in that department, has kindly allowed me to reproduce Fig. 1 taken from his paper (B. M. Hibbard, personal communication). It will be seen that as more classes of Rh-negative women have become eligible for treatment so the incidence of Rh immunization (and of exchange transfusion) has declined.
Canada. Here the failure rate is extremely low and this is probably related to the fact that many women are excluded from treatment who would probably be given anti-D antibody in other centres. This is because Canadian workers, using particularly sensitive enzyme techniques, find a much higher incidence of primary immunization during pregnancy (about 2% as against about 0.8% elsewhere; Chown, 1968) . To combat this, Canada was early on the scene with ante-natal treatment (Zipursky, Pollack, Chown & Israels, 1965) and a large-scale trial has now been instituted in which anti-D antibody is given in the last trimester of pregnancy as well as after delivery. The results will not be known for some time but a preliminary report shows that the foetal cell scores both during pregnancy and after delivery are decreased as compared with controls (Bowman, 1970) .
There is an unconfirmed report from Toronto (P. L. Mollison, personal communication) of a severe reaction to anti-D antibody, probably due to anti-IgA antibody.* This might occur in an individual who lacked IgA and where the anti-D antibody contained traces of IgA. Such reactions are well documented after plasma and blood transfusions, but, as far as I know, have not previously been reported with intramuscular injections.
Australia. An ante-natal trial has also been started in Australia and the details of this and some results are shown in Table 3 (M. G. Davey, personal communication). Though the numbers are not yet large enough to be able to draw any conclusions, it is established that anti-D antibody does no harm to the baby, although occasionally its erythrocytes give a positive Coombs test.
Davey also reports that in Australia generally there has so far been no reduction in the immunization rate or in the number of exchange transfusions. If 'priming' (see later) is the chief cause of failures, it is difficult to know why intravenous therapy is better than intramuscular, but delay in absorption, particularly in fat people, may be a disadvantage in the intramuscular route. South Africa. In Johannesburg Shapiro has extensive experience of anti-D plasma and thinks it is preferable to y-globulin; he considers that with suitable precautions the risk of serumtransmitted hepatitis is negligible [M. Shapiro, personal communication, see Clarke (1970) for details].
Holland. E. Borst-Eilers (personal communication) reports that in 1970 anti-D immunoglobulin was given to 80% of Rh-negative women giving birth to an Rh-positive baby. An attempt is being made to raise this figure to 100%. She reports that in the University Hospital in Amsterdam the number of exchange transfusions in 1970 was half of that in 1969 (seven as against fifteen).
Finland. Eklund & Nevanlinna (1971) report the results of a 2-year clinical trial making use of 250 ,ug of y-globulin. Of 792 control mothers with ABO compatible infants, 4.3% were found to be immunized during the post-delivery period. Out of 4172 treated mothers, five had developed Rh antibodies (0.12%). Of 175 mothers tested at the end of a subsequent Rh-positive pregnancy, none had Rh antibodies. The particular interest of the trial is that the authors also treated mothers after ABO incompatible pregnancies. Out of 221 controls, one developed antibodies 3 months after delivery, while in the treated group of 1343 mothers five failures were observed. The results probably indicate that the administration of anti-D antibody does not influence the protective effect of ABO incompatibility.
Against this it is of interest that in the United Kingdom, Mollison calculates that there is a 3% Rhesus immunization rate in untreated ABO-incompatible cases, and he thinks that anti-D antibody should be used here. The reason for the differences between the Finnish and the United Kingdom figures is uncertain, but in Finland they are consistent in that there is a lower immunization rate in all the classes. Hungary. While we know from the XI1 International Congress of Blood Transfusion in Moscow (1969) that many countries in Eastern Europe have programmes of prophylaxis, our most up-to-date information (Table 4) 
Failures of prophylaxis
It seems highly probable that the principal cause of the small failure rate is previous 'priming'. By this is meant immunization, but with the Rh antibodies not being detectable by routine tests, though their effect can be demonstrated by erythrocyte survival studies (see Table 5 ).
A case of our own demonstrates this phenomenon. A 70-year-old Rh-negative volunteer had no demonstrable antibodies by routine tests and was injected with 5 ml of Rh-positive foetal blood. Twenty-four hours later there were a large number of foetal cells in his blood film, but at 48 h these had all disappeared and anti-D antibody was demonstrable. It was then found that he had had a blood transfusion in World War I which had clearly 'primed' him. Had he been a woman and 50 years younger he might well have been considered a case for treatment and would have been classed as a failure 6 months later. It is uncertain how often priming occurs, but we think it must be a fairly rare event as otherwise the failure rate would be higher. One way in which the matter can be assessed is by comparing the frequency in Rh-negative women of a foetal cell score of 0 according as to whether the baby is Rh-positive or negative (where no priming can occur). Table 6 shows some Australian figures prepared by Davey (1971) . They are clearly not significantly different from each other but only a very small order of magnitude is being looked for and much larger numbers are necessary to see if the differences are really significant. On the data available Davey thinks the risk of priming is of the order of 1%, while Jsrgensen & Freiesleben (1971) think it is higher (3%).
A much less frequent cause of failure is the inadequate dosage of anti-D and this is only likely to arise with a mismatched blood transfusion, where the volume of incompatible blood can be very great. The experiments of Pollack, Ascari, Kochesky, O'Connor, Ho & Tripodi (1971) , in a large number of Rh-negative male volunteers give by far the most extensive information on the subject (Table 7) , and it will be seen that the standard dose of y-globulin protects up to 35 ml of packed erythrocytes. Other points of interest are, first, that in the controls only 65% became immunized even with 100 ml of erythrocytes and, secondly, that in the treated cases when the failures began to occur they did not rise in the same proportion as in the controls, even though the injected antibody would have disappeared well before the booster injection. Pollack and his colleagues think this is consistent with the view that the coating of the cells by the earlier injected antibody has continued to interfere with processing by the macrophages. (Pollack et al., 1971) . Six groups of male Rh-negative volunteers were injected as indicated. Three days later, 267 pg of anti-D antibodies or 1 ml of normal IgG was given to treated or control series respectively. Serum samples were obtained from each man at monthly intervals for 6 months. Each volunteer was then given 0.2 ml of blood intravenously as a 'booster', and a serum sample was obtained 1 week later. A cause of failure which is just possibly important concerns the lack of heterogeneity of the anti-D antibody. Hummel(l970) raised anti-D antibody in one of a pair of identical twin Rhnegative male volunteers, and found that this antibody did not protect the co-twin when he was injected with the same type of Rh-positive cells as his brother. Hummel thinks this is because the antibody is 'homogeneous'. However, we feel that the evidence for this is inconclusive, since in his paper the proper control is not reported. This would be an unrelated Rh-negative person injected with the same type of Rh-positive blood and then given the anti-D antibody from the first twin.
'Failures', or 'when is an antibody not an antibody?'
One of the difficulties in assessing failures is to decide whether an antibody detectable by enzyme techniques only is the remains of the injected passive antibody or whether it represents the beginning of active immunization. While the latter is usually characterized by 19s anti-D antibody, this is not always the case and one may have to adopt a 'wait-and-see' attitude, the only sure criterion being a negative Coombs test on the cord blood of the next Rh-positive baby (see Murray, 1971 ). In our experience in Liverpool this has in fact almost always been the case with treated women who had enzyme antibodies at 6 months.
Problems remaining to be solved
Primary immunization during pregnancy. We feel that the reason that immunization to the D antigen so rarely occurs during pregnancy is that the effective TPH usually takes place at or near delivery and that the Rh antibodies take weeks or months to form. An alternative view is that during pregnancy there is a relative state of maternal anergy such that the woman does not a readily respond to primary immunization. Woodrow, Elson & Donohoe (1971) tested this hypothesis (for haemagglutinating antibodies) in the rabbit, and Fig. 2 shows that pregnant does can just as readily be immunized to an erythrocyte antigen as those which are not pregnant. Cellular immunity may, however, be diminished during pregnancy, since it is known that the Mantoux reaction is weaker at this time. However, this does not appear to be relevant to blood group incompatibilities between mother and foetus causing HDN, though it may be important in preventing rejection of the foetus.
Pregnant
Hg" negative robbits 18 10155.6°/o) 10 (556%) Anti -Hg" present No.
Assessing a secondary stimulus-rosette formation. Elson 8z Bradley (1970) found that isolated washed mononucleated cells from the blood of immunized Rh@)-negative pregnant women sometimes had the ability to form rosettes with Rh(D)-positive erythrocytes but not with Rh @)-negative ones (Plate 5). This observation was followed by a series of studies on Rhesusimmunized male volunteers and from them it appeared that the Rh-positive erythrocytes are bound to the rosette-forming mononucleated cell which has an antibody-like receptor present on the surface, but rosette formation is blocked by anti-human IgG. It seems likely that rosette formation is an indication of a second antigenic stimulus having occurred, but the presence of rosettes does not give any indication as to when this took place since in the volunteers mentioned above they were found in one case 3 years after the last stimulus. However, if it could be shown that there had been an increase in the number of rosettes over a few weeks, this would be suggestive evidence of a recent TPH in a patient already immunized.
Specificity of protection by anti-D antibody. Most animal work suggests that suppression of the immune response by the giving of passive antibody is specific for a particular antigenic determinant. Pollack, Gorman, Hager, Freda & Tripodi (1968) in the U.S.A. and Woodrow et al. (1971) in our Unit, injected HgAF-negative rabbits with HgAF-positive cells and then gave anti-HgA serum. Both groups of workers found that only the response to HgA was suppressed, the animals making anti-HgF normally. Whether this is true with Rh in man remains to be seen, but the writer feels it is more likely that anti-D antibody works in a non-specific way, i.e. that it will protect not only against anti-D antibody, but against other erythrocyte antigens as well. In favour of this, the protection afforded by ABO incompatibility is nonspecific and in a large series of patients in Liverpool treated by anti-D antibody very few other antibodies have been found when these have been looked for, whereas Queenan, Smith, Haber, Jeffrey & Gadow (1969) found 299 'irregular' antibodies in 18 378 consecutive (untreated) obstetric patients.
An experiment designed to test which of the two hypotheses is correct is at present being undertaken in Liverpool. Sixteen Rh-negative, Kell-negative male volunteers have been divided into groups of four, and half the men act as controls. They are all given 1 ml of 51Cr-labelled Rh-positive Kell-positive packed erythrocytes, and the treated group are then given a dose of anti-Kell y-globulin. This was obtained from a naturally immunized woman and though it only contains 8 pg of anti-Kell antibody/ml, it had been shown to be biologically very active as far as her pregnancies were concerned. It has been found that 2 ml, i.e. 16 pg, very quickly clear the injected Kell-positive Rh-positive cells and that these are taken up by the spleen. The men are being followed up and all are given a booster dose of Rh-positive Kell-positive blood about 16 weeks later, with the treated getting another injection of anti-Kell antibody. This procedure will be undertaken three times in all, if necessary. At the time of writing, after the first stimulus, one out of four controls has produced anti-D and none out of those treated with anti-Kell antibody. The final results are awaited with the keenest interest in our Unit, since opinion is nicely divided as to the outcome.
